Answer
It is unknown whether diroximel fumarate or its metabolites pass into human breast milk; risk to newborns or infants cannot be excluded, and stopping breastfeeding or Vumerity therapy must be considered based on the benefits to the child and woman.
Sources for this answer
- Vumerity 231 mg gastro-resistant hard capsulesBiogen Idec Ltd · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 6Document updated
Sources checked